GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Valneva SE (NAS:VALN) » Definitions » Cash per Share

Valneva SE (Valneva SE) Cash per Share : $1.98 (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Valneva SE Cash per Share?

Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities divided by Shares Outstanding (EOP). Valneva SE's Cash per Share for the quarter that ended in Dec. 2023 was $1.98.

Valneva SE Cash per Share Historical Data

The historical data trend for Valneva SE's Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Valneva SE Cash per Share Chart

Valneva SE Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.58 5.48 7.46 4.39 1.98

Valneva SE Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.39 3.94 3.19 2.63 1.98

Valneva SE Cash per Share Calculation

This is the ratio of a company's available cash, including easy to liquidate short-term investment, to its total number of shares outstanding. The result indicates the percentage of a company's share price that is available to spend on company's activities, such as strengthening the business, paying down the debt and making dividend payment to shareholders. It's a reliable indicator of a company's financial health.

Valneva SE's Cash per Share for the fiscal year that ended in Dec. 2023 is calculated as:

Cash per Share= Cash, Cash Equivalents, Marketable Securities /Shares Outstanding (EOP)
=137.491/69.4
=1.98

Valneva SE's Cash per Share for the quarter that ended in Dec. 2023 is calculated as:

Cash per Share= Cash, Cash Equivalents, Marketable Securities /Shares Outstanding (EOP)
=137.491/69.4
=1.98

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Valneva SE  (NAS:VALN) Cash per Share Explanation

Cash per Share represents the liquidity of a compant's assets. A high level of Cash per Share suggests that there's enough money on hand for a company to cover any emergencies and that the company has adequate money to reinvest its business or pay dividends to investors. However, if the ratio is too high, it can also suggeust the inefficiency of management for not making a full usage of the cash.

Valneva SE Cash per Share Related Terms

Thank you for viewing the detailed overview of Valneva SE's Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Valneva SE (Valneva SE) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Valneva SE (NAS:VALN) » Definitions » Cash per Share
Comparable Companies
XPAR:MEDCL XPAR:NANO XPAR:ALSEN XPAR:ALCLS XPAR:IPH XPAR:IVA XPAR:AELIS XPAR:ABVX XPAR:GNFT XPAR:DBV OCSE:NOVO B VRTX REGN ASX:CSL XKRX:207940 MRNA XKRX:068270 XBRU:ARGX XBRU:UCB BNTX
Traded in Other Exchanges
INRLF:USA VLA:France AYJ:Germany VLA:Austria
Address
6 Rue Alain Bombard, Saint-Herblain, FRA, 44800
Website
https://www.valneva.com
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes two vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, & third-party products; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The majority is from the Commercialized vaccines segment & geographically from the United States.